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Abstract: Icatibant (Firazyr®) is a novel subcutaneous treatment recently licensed in the 
European Union for acute hereditary angioedema. Hereditary angioedema, resulting from 
inherited partial C1 inhibitor deficiency, is a disabling condition characterized by intermittent 
episodes of bradykinin-mediated angioedema. Icatibant blocks bradykinin B2 receptors, atte-
nutating the episode. Randomized double-blind, placebo-controlled trials of icatibant, showed 
significant superiority over oral tranexamic acid in 74 European patients and a trend to improve-
ment in a similar US trial comparing icatibant with placebo in 55 patients. Outcomes for several 
endpoints did not reach significance in the US trial, perhaps because of low participant numbers 
and confounding factors: a further trial is planned. Open label studies have shown benefit in 
multiple treatments for attacks at all sites. Approximately 10% of patients require a second dose 
for re-emergent symptoms, usually 10 to 27 hours after the initial treatment. Its subcutaneous 
route of administration, good tolerability and novel mode of action make icatibant a promising 
addition to the limited repertoire of treatments for hereditary angioedema.
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Hereditary angioedema: clinical features  
and current management of acute attacks
Hereditary angioedema (HAE) is an autosomal dominant disorder resulting from a 
partial deficiency of C1 inhibitor (C1-INH). Those affected experience intermittent 
cutaneous or mucosal swellings or ‘attacks’, lasting between 1 and 5 days.1,2 Swellings 
affecting the skin are typically painless but may cause disfigurement, or difficulty 
driving or operating machinery if hands or feet are involved. Cutaneous swelling of 
the genital area may occasionally lead to retention of urine. Intra-abdominal edema, 
affecting bowel segments or viscera, is usually very painful, may be associated with 
vomiting and/or diarrhea, is occasionally mistaken for a surgical emergency and typi-
cally leads to temporary disablement, with full recovery after several days.3,4 By contrast, 
laryngeal attacks may be fatal. Lifetime fatality rates have been estimated at between 
10% and 30%5 and 25% of families surveyed in the European HAE register reported 
an HAE-related fatality, almost exclusively caused by laryngeal edema.6,7 Because 
the episode fatality rate of laryngeal edema is relatively low, patients may experience 
many such attacks which resolve spontaneously or with treatment, and therefore may 
fail to treat laryngeal symptoms as a medical emergency. Conversely patients may be 
so fearful of laryngeal swelling that they are unwilling to risk being unable to obtain 
emergency treatment by traveling any distance from their local hospital, resulting in 
social and employment difficulties.Vascular Health and Risk Management 2010:6 796
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Prophylaxis for HAE attacks is available; either with 
attenuated androgens which increase hepatic production 
of endogenous C1 inhibitor, or by antifibrinolytics such as 
tranexamic acid or ε−aminocaproic acid (EACA) which may 
exert a C1-INH sparing effect.9,10 However, efficacy of these 
agents is variable and most patients continue to experience 
intermittent swellings albeit at a reduced frequency. Attenuated 
androgens are associated with androgenic side-effects such 
as amenorrhea, weight gain, mood changes or hirsutism; and 
hepatitis or the development of adenomas.9,11,12 Therefore 
many patients find prophylactic agents insufficiently effective 
or have unacceptable side-effects.
For acute HAE attacks, tranexamic acid is of very limited 
benefit and attenuated androgens are not effective. Until 
recently, C1-INH has been the sole option for acute treatment. 
C1-INH is purified from the pooled plasma of volunteer 
donors and is subject to one or more additional treatments 
to minimize risk of pathogen transmission. Current C1-INH 
concentrates have proven safe and effective in double-blind 
placebo-controlled trials9,13–18 and in clinical practice14,19–22 
C1-INH is also effective in prophylaxis.23–25 Availability has 
been limited by licensing status, expense, its human source 
and requirement for intravenous administration, and until 
recently it has not been available at all in several countries, 
including the US.
Icatibant (Firazyr®; Shire), a bradykinin B2 receptor 
inhibitor, was licensed in the EU, Switzerland, Lichtenstein 
and Iceland in July 2008 for treatment of acute HAE-related 
swellings. A concurrent marketing application was turned 
down by the US Food and Drug administration (FDA), pend-
ing the results of a confirmatory placebo-controlled phase 
III trial. Icatibant has orphan drug status in Australia, EU, 
Switzerland and the US.
This review examines the evidence supporting use of this 
agent and considers its place in management of hereditary 
angioedema.
Pathophysiology of HAE  
and role of iatibant
C1 inhibitor is a serpin whose principal function is the 
regulation of local inflammation. It inhibits C1r/s in the 
classical complement pathway, kallikrein and factors XI 
and XII (Hageman factor) of the contact pathway and plasmin 
of the thrombolytic pathway. It also has a role in the control 
of the alternative and mannan binding ligand pathways.26 
Genetic mutations of the C1-INH gene on chromosome 11 
give rise to reduced levels (HAE type I) or reduced function 
(HAE type II) of C1 inhibitor. At times of physiological 
stress, patients with HAE may have insufficient endogenous 
local C1-INH, resulting in excessive local vasodilatation 
and edema. Estrogens27 trauma,6,28,29 minor infection29,30 or 
psychological stress,31 may precipitate attacks; however, for 
the majority of attacks, the trigger is unknown.26,32
Current evidence favors bradykinin as the principal 
mediator of edema in HAE: Patients with HAE have raised 
plasma levels of bradykinin compared with normal controls. 
Levels increase further during attacks. Local bradykinin 
concentrations are much higher at the site of swelling than at 
unaffected sites26,32–36 One unusual family had a C1 inhibitor 
mutation with preserved kallikrein inhibitory function and 
presumably normal bradykinin. Members of this family had 
low classical pathway complement levels, typical of HAE, 
but no swellings, presenting instead with lupus (secondary to 
acquired deficiency of early classical pathway complement 
components).37
Bradykinin acts on two types of receptors. Inducible 
B1 receptors probably mediate pain and possibly erythema, 
while activation of constitutive B2 receptors causes local 
vasodilatation and edema. Icatibant is a synthetic decapeptide 
and competitive inhibitor of bradykinin B2 receptors. It exerts 
its action in HAE by antagonizing the vasodilatory effect of 
excess bradykinin.
Chemistry
The active decapeptide of icatibant; H-D-Arg-Arg-Pro-Hyp-
Gly-Thi-Ser-D-Tic-Oic-Arg-OH is synthesized in a solid 
phase peptide synthesis process. Thus, unlike C1 inhibitor, 
it does not contain human or other animal material. Icatibant 
is stable for up to 24 months at 5°C, and for up to 6 months 
at 25°C. This relatively long shelf life is important; current 
advice is that patients should keep at least one acute treatment 
at home and the majority of patients require only infrequent 
treatments.38,39 It is supplied as a 3 mL pre-filled syringe for 
subcutaneous injection.40
Pharmacokinetics
Icatibant is a specific competitive antagonist with similar 
affinity to bradykinin (1–10 nM) for the B2 receptor, while 
affinity for the B1 receptor is 100-fold lower. In vitro studies 
did not reveal activity on other receptors or enzymes, including 
the cytochrome p450 system, thus major drug interactions 
were not predicted by these preclinical studies. Icatibant is 
rapidly absorbed after subcutaneous administration, although 
individuals may show variation in its absorption rate of 
up to 25%. Maximum concentrations are reached within 
30 minutes and bioavailability is high at around 97%.40,41 Vascular Health and Risk Management 2010:6 797
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Relatively fast absorption is essential since rapid symptom 
control is required. Intravenous administration was investi-
gated but did not offer pharmacokinetic benefit and was less 
convenient than subcutaneous injection. Icatibant has low 
protein binding at around 44% and the volume of distribution 
is 20 to 25 L, consistent with distribution to include sites 
of swelling. Animal studies indicate that icatibant is poorly 
distributed into adipose tissue and does not appear to cross 
the blood brain barrier. However, it does cross the placenta 
and is excreted in breast milk in rats.40
Icatibant is metabolized in the liver by cleavage to 
2 smaller peptides; metabolites (90%) and intact icatibant 
(10%) are excreted via the kidney. Half-life of icatibant and 
its metabolites is 1 to 2 hours. Pharmacokinetics appears 
unaffected by liver and renal impairment in animal studies. 
Human studies of icatibant, for resistant ascites in patients 
with cirrhosis of the liver, some of whom had concomitant 
renal impairment did not raise safety concerns.40 Icatibant 
pharmacokinetics do not appear to depend on weight or 
gender but clearance is reduced in the elderly with area 
under the curve increased by 5% to 60% in an 80-year-old 
compared with a 40-year-old patient.40
Pharmacodynamics
Bradykinin inhibition studies with healthy human volunteers 
showed a mean EC50 (concentration at which 50% of the 
measured effect of bradykinin was inhibited) of 7.3 to 10.8 nm 
depending on the method used. Based on these preclinical data 
and the results of an open label trial (discussed later)40,42 30 mg 
was selected as the optimum subcutaneous dose. Since the 
duration of action of icatibant appeared relatively independent 
of dose within the therapeutic range, administration of a 
second (and third) 30 mg dose when indicated appeared more 
logical than use of a higher single dose.
In rodents, partial bradykinin agonist activity was 
apparent at supra-therapeutic doses of 3.2 mg/kg or higher.40 
Concentrations sufficient to produce these effects may occur 
locally and may account for local reactions after subcutaneous 
injection. Except in the case of overdose, they are otherwise 
unlikely to occur in clinical use.
Clinical data
One pilot unblinded and 2 double-blinded studies have 
been completed. Patients taking part in the double-blind 
studies were treated for subsequent attacks with open label 
icatibant.
The phase II open label dose finding study involved 
20 attacks in 15 patients, treated with single intravenous (iv) 
infusions or subcutaneous (sc) injections (0.4 mg/kg over 
30 minutes or 2 hours; or 0.8 mg/kg [iv] over 30 minutes; 
or 30/45 mg [sc]).40,43
The phase III trials were randomized, double-blinded trials 
comparing a single 30 mg sc dose of icatibant with placebo 
(For Angioedema, Subcutaneous Treatment (FAST)-1; US, 
Canada, Argentina, and Australia) in 56 patients; or the active 
comparator, tranexamic acid (FAST-2; EU and Israel) in 
74 patients. An additional 10 patients with laryngeal edema 
were treated with open label icatibant.40,44 One further patient 
in the US study experiencing onset of laryngeal symptoms 
after treatment with placebo was given rescue treatment with 
icatibant. The phase III studies included open label phase 
extensions for treated patients and for those enrolled but not 
treated prior to the end of the double-blind phase.40
In all trials, outcomes were measured using a 100 mm 
visual analog scale (VAS, detailed in Figure 1) reported by the 
patient for the main, and (in the phase II studies) secondary 
symptoms. In the phase III studies, additional outcome 
assessments were made by patient and physician, using a 5 or 
7 point symptom score for individual HAE-related symptoms 
and global wellbeing respectively.
In the phase II study, patients with a variety of peripheral 
or abdominal attacks were treated at between 6 and 
10 hours after the onset of symptoms. Results suggested 
that subcutaneous administration of icatibant was at least as 
effective as intravenous, with median time to first response 
of around 1 hour (iv) or 30 minutes (sc); 30% improvement 
(time to onset of resolution; TOR30) at 2 to 5 hours and 
almost complete (90%) resolution (TOR90) at around 
8.5 to 16 hours. No clear differences were seen over the 
dose range tested. On this basis, 30 mg sc was selected for 
further study.43
Both phase III studies included adults (18 years) with 
HAE, experiencing a moderate or severe attack at any site. 
Study treatment was administered within 6 hours of the 
attack becoming moderate in severity (3/10 on the VAS 
scale). Those with laryngeal symptoms were treated with 
icatibant on an open label basis, while those with attacks 
at other sites (the majority) were randomized to 30 mg 
icatibant subcutaneously into the anterior abdominal wall, or 
comparator (oral tranexamic acid 1 g 3 times daily for 3 days 
in FAST-2; placebo in FAST-1) in a double-blind fashion. 
The primary endpoint was the time to onset of symptom 
relief, as measured by sustained improvement of at least 
30% on the VAS scale (TOR30), assessed for the principal 
symptom (for example cutaneous swelling or abdominal 
pain). Secondary endpoints were response rate at 4 hours Vascular Health and Risk Management 2010:6 798
Longhurst Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
after treatment, time to relief of secondary symptoms, time to 
start of improvement according to patient, time to observable 
regression of visible swelling, global assessment and overall 
patient improvement and, at week 24, a patient satisfaction 
questionnaire.
In both studies, patients improved more quickly with 
icatibant, with a median time to onset of symptom relief 
(TOR30) of 2.0 hours compared with 12.0 hours for 
tranexamic acid (FAST-2) and 2.5 compared with 4.6 hours 
for placebo (FAST-1). The difference was statistically 
significant for FAST-2 but not for FAST-1. Improvement of 
the secondary endpoints was faster in the icatibant treated 
groups. The improvement was significant for the majority 
of endpoints in FAST-2 but not FAST-1, where parameters 
showed a non-significant trend to improvement.
Figure 1 shows the mean VAS values over time for the 
symptom used for the primary endpoint.
Rescue medication
More rescue medication, including narcotic and other 
painkillers, was administered to patients who received 
placebo or tranexamic acid compared with those who received 
icatibant. In FAST-1, 11 patients randomized to placebo 
required rescue medication within 12 hours and a further 
14 required rescue medication within 48 hours, compared 
with 3 patients in 12 hours and 6 within 48 hours for 
patients receiving icatibant. Similarly in FAST-2, 5 patients 
randomized to tranexamic acid required rescue medication 
within 12 hours and 11 required rescue medication within 
48 hours, compared with 0 patients in 12 hours and 5 within 
48 hours for patients receiving icatibant.44.45 The need 
for additional rescue medication suggests inferior symptom 
control in the comparator arm, and conversely may have 
contributed to the lack of significance (P  0.05) in some 
parameters of the FAST-1 trial.
Open label treatments
Data are available on a further 118 patients experiencing 
597 HAE attacks treated with icatibant in the open label 
extensions of FAST-1 and FAST-2. Of these, 59 (9.9%) 
patients’ symptoms recurred, all but 3 patients more than 
10 hours after icatibant administration. Of these patients 
60.9% were treated with a further injection of icatibant. Four 
patients (0.7% of the original group) were treated with a third 
injection of icatibant.40
More recently Malbrán et al have described their experience 
of treating 163 attacks in 19 patients in Argentina. Time to 
subjective improvement was an average of 37.9 minutes. One 
of 102 patients analyzed received a second dose because of 
insufficient response at 6 hours, 13 of 102 (12.7%) reported 
an exacerbation of symptoms within 48 hours, of whom 
6 received a second dose of icatibant with relief.46 Similarly, 
Reshef et al report mean (SE) times to response for 40.6 (18.3) 
minutes for 25 abdominal attacks and 57.7 (26.4) minutes for 
38 cutaneous attacks in 15 patients.47
Laryngeal attacks
A total of 61 laryngeal attacks of all severities, in 36 patients, 
have been treated during the FAST trials, including the open 
label extensions.40,44 Time to first symptom improvement 
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Figure 1 improvement of symptom severity at 4 hours and 12 hours (FAST-1 and FAST-2).40
Notes:  when completing the visual analog score (VAS), the patient is asked to put a mark on a 100 mm line, according to the severity of each symptom.   The left end of the 
line represents absence of the symptom and the right end of the line represents the most severe symptom imaginable. Distance of the mark along the line gives a measure of 
symptom severity.   Triangles represent FAST-1; quadrilaterals represent FAST-2.Vascular Health and Risk Management 2010:6 799
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according to the patient ranged from 0.3 to 3.6 hours (FAST-2) 
and 0.3 to 2.4 hours (FAST-1). Requirement for a second 
icatibant injection appeared similar to that required for attacks 
at other sites at 10% (5 of 50 eligible attacks). One patient 
with laryngeal edema required intubation 5 minutes after the 
administration of icatibant.40 However, neither icatibant nor 
replacement therapy with C1 inhibitor concentrate would 
be expected to take effect within this timescale. Although 
not directly comparable, response time seems similar to 
that reported for C1 inhibitor treatment, although recurrent 
angioedema seems to be less frequent with C1 inhibitor.18,19
Multiple attacks
Efficacy of icatibant appears similar in patients receiving 
up to 110 repeated treatments for multiple attacks. For each 
attack, the requirement for a second or third dose of icatibant 
remained constant at around 10% or 1% respectively. There 
is no method for measuring icatibant antibodies but the low 
antigenic potential in animal studies (as seen with other short 
peptides) and the multiple treatment data provide some reas-
surance that this is unlikely to be a major problem.40
Recurrent attacks
The observed need for more than one injection in 10% is 
potentially of concern. Recurrent attacks are likely to be 
a consequence of the short half-life of icatibant, although 
continuing overactivation of other inflammatory pathways 
controlled by C1 inhibitor may contribute. Further information 
on recurrent attacks is available from Bork’s dose-finding 
study. Of the 20 HAE attacks, 5 attacks in 4 patients recurred 
between 14 and 27 hours after the initial treatment, albeit not 
all treatments were at optimal dose or route. Four attacks 
recurred at the same site and one at a different site. All were 
mild and were treated with C1 inhibitor.42 These observations 
are similar to experience in UK, where recurrence generally 
occurs the following day and is of slow onset, usually at the 
same site. We have observed that recurrence appears much 
more likely in patients with very frequent attacks.48 Thus, 
it is important that patients are aware of the possibility of 
recurrence and have a plan for this eventuality.
Side effects
injection site reactions
Most patients receiving subcutaneous icatibant experience 
injection site reactions. Erythema, swelling and pain at 
the injection site lasted from 10 minutes to several hours. 
However, the reactions are generally tolerated well without 
need for additional analgesia.42,48 These symptoms are most 
likely caused by partial agonist activity.
Systemic reactions
In clinical studies, the majority of the adverse events 
appeared to be related to the HAE. A total of 1002 subjects 
have received icatibant, by the intravenous, subcutaneous, 
intranasal, inhalational or intra-articular routes, in trials for 
a variety of indications, with adverse reaction rate (excluding 
local reactions) similar to placebo.40
Bradykinin is important in protecting ischemic tissues; 
animal models suggesting poorer outcomes in myocardial 
ischemia/infarction after icatibant treatment. For this reason 
icatibant is not recommended for use in the presence of acute 
cardiac or brain ischemia. Bradykinin antagonism might be 
expected to increase blood pressure. However, no hypertensive 
effect at therapeutic doses was seen in clinical or animal trials. 
Because of icatibant’s short half-life and intermittent use, it 
would be unlikely to exert a chronic hypertensive effect.
Icatibant has been used in a trial for resistant ascites 
in liver cirrhosis, which included participants with severe 
liver and renal impairment, appearing well tolerated in this 
vulnerable group.40
Discussion
Icatibant is the first new treatment to be made available for 
HAE since the advent of C1 inhibitor over 25 years ago, 
Table 1 Recurrent symptoms reported in dose finding pilot study of icatibant43
Patient age 
(years)/sex
Site of primary 
attack
Time after administration 
of icatibant of recurrence 
(hours)
Severity of 
recurrence
Site of  
recurrence
43F Abdominal 14 Unknown Abdominal
Abdominal 17 Unknown Abdominal
47M Skin/abdominal 20 Mild Skin/abdominal
31M Skin/abdominal 20 Unknown Skin
53F Skin (foot) 27 Unknown Skin (foot)Vascular Health and Risk Management 2010:6 800
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and is a very welcome addition to the limited therapeutic 
options available for this disorder. It has not yet been formally 
evaluated in other bradykinin-mediated angioedemas. 
However, it would be a logical choice in acquired angioedema 
due to C1 inhibitor deficiency, especially where large doses 
of C1 inhibitor would otherwise be required.23,49 It could 
potentially be of use in angiotensin converting enzyme 
(ACE) inhibitor-related swelling, and in HAE3, which in 
some cases at least, is associated with factor XII mutations 
and consequent bradykinin overproduction,50 although it 
has not been tested for these indications. Other medications 
in development for HAE include ecallantide (DX88), 
a kallikrein inhibitor. Like icatibant, it has the advantage 
of subcutaneous administration and has shown promise in 
placebo controlled trials. Ecallantide inhibits kallikrein, 
thus reducing bradykinin production and preventing 
further swelling.51 It is currently unlicensed. Rhucin, 
a recombinant C1 inhibitor, given intravenously, is also 
currently unlicensed.52–54
There have been no head-to-head trials comparing 
icatibant with C1 inhibitor concentrate, or other acute 
treatments. Studies of emergency treatment where patients 
need to travel, sometimes for several hours, to get treatment 
in the trial center are logistically difficult. This, together with 
the low prevalence of HAE, makes it unlikely that such trials 
will ever take place. While not being directly comparable, 
results of studies of C1 inhibitor in acute HAE suggest 
that the icatibant and C1 inhibitor are broadly similar in 
terms of onset of relief and time to complete resolution of 
symptoms.15–18,40
In the European (FAST-2) trial, icatibant showed a 
significant benefit compared with tranexamic acid. By 
contrast, while showing a marked trend in favor of icatibant 
in the US (FAST-1) trial, the difference between icatibant 
and placebo did not reach significance for several endpoints, 
including the primary end point.40 This is likely to result from 
underpowering, since the low numbers were randomized for a 
treatment where delayed and variable responses are expected, 
and where the outcome measures are subjective. Additionally 
the use of intravenous rehydration, pain relief – including 
with opiates – and other symptomatic measures was greater 
in the placebo group. These almost certainly contributed to 
the greater than expected improvement in the placebo group, 
which was of sufficient magnitude to reach the endpoint of 
30% improvement in several cases.40 The ongoing FAST-3 
trial will provide additional efficacy data.
Icatibant, with a half-life of around 2 hours, is short-acting 
compared to C1 inhibitor (half-life 30–64 hours),5,26,32,42 
and to the duration of a typical acute attack, which is 
1 to 5 days.1,4  This is the likely explanation for recurrent 
swellings. In practice, recurrence appears a relatively unusual 
event with only around 10% of attacks requiring more than 
1, and 1% requiring more than 2 injections. Since icatibant 
does not replace C1 inhibitor, attenuate contact pathway or 
complement activation, or reduce bradykinin production, this 
may at first appear surprising. Icatibant stops the progression 
of edema, and allows physiological resolution. Edema may 
recur if the effect of icatibant wears off while bradykinin 
levels are still elevated. However, the recurrent edema will 
often be subclinical since fluid accumulated does not reach 
a sufficient volume to produce symptoms before natural 
resolution of the attack.
Treatment of acute HAE with C1 inhibitor is most 
effective when given early.20 However, C1 inhibitor’s intra-
venous route of administration can result in delays in gain-
ing access to treatment. This has been partially addressed 
by the development of home therapy/self administration 
programs.24,55–57 Self-administration of C1 inhibitor requires 
a high degree of patient motivation and support, and the 
majority of patients who have only infrequent attacks may 
be less motivated to undergo the necessary training. This is 
important, since failure to access emergency treatment in a 
timely manner is the major contributor to the employment, 
educational and social difficulties associated with HAE, 
as well as to mortality. The availability of a licensed subcu-
taneous treatment will facilitate administration by local and 
community-based healthcare staff without requirement for 
up to date intravenous skills. Assuming the reassuring safety 
record of icatibant is confirmed in clinical use, the true place 
for icatibant seems likely to be in self-administration, where 
it has potential to address a significant unmet need. In this 
respect, it may have an advantage over ecallantide, which has 
been associated with anaphylactoid-like symptoms.58
Home therapy programmes for children are less well 
established, perhaps due to the lower frequency of acute 
attacks prior to adolescence59 or anticipated greater technical 
difficulties with intravenous access. There is a lack of 
effective prophylactic options for children since attenuated 
androgens are not recommended pre-puberty.38,39 For the 
few children who have frequent attacks, a subcutaneous 
acute treatment would be an attractive option, although the 
pain associated with icatibant injections may be a problem. 
Repeated doses of icatibant administered to juvenile animals 
resulted in reversible delay in sexual maturation.40 Further 
information would be necessary before icatibant could be 
recommended for trials in this age group.Vascular Health and Risk Management 2010:6 801
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Attenuated androgens are contraindicated in pregnancy. 
Therefore many pregnant women experience an increased 
frequency of attacks because of lack of effective oral 
prophylaxis and hormonal changes.39,60 Animal studies have 
shown that icatibant does not appear to have genetic toxicity 
nor cause structural damage to embryos.40 No human data are 
available and therefore C1 inhibitor concentrate, for attacks 
or prophylactically, must remain the treatment of choice for 
this difficult to treat group.
Despite only recently gaining a licence in many EU coun-
tries and in the US, C1 inhibitor has been used extensively for 
HAE and has an impressive record.22,54,61,62 It seems likely that 
both C1 inhibitor and icatibant will be used, perhaps at dif-
ferent times in the same patient, according to circumstances. 
The advent of a second, complementary treatment option is 
a major step forward for this orphan disease.
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